Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guangdong Zhongsheng Pharmaceutical Co (002317) Fair Value & Analysis

Healthcare · CN · Market cap 18.7B CNY

Price¥22.12
Fair Value¥5.37
Upside-75.7%
Quality93/100
Evidence: High Range ¥3.98 – ¥6.98

Fair value as of: Jun 25, 2026

Analysis

Guangdong Zhongsheng Pharmaceutical Co (002317) currently trades at ¥22.12, while our model-based Fair Value estimate is ¥5.37 — implying the stock looks roughly 75.7% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Guangdong Zhongsheng Pharmaceutical Co (002317) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥5.37 versus a price of ¥22.12 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002317?
Our 21-model fair value for Guangdong Zhongsheng Pharmaceutical Co is ¥5.37 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥22.12.
What is the quality score of 002317?
Guangdong Zhongsheng Pharmaceutical Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.